Digibind is primarily used in cases of severe digoxin toxicity, which can manifest through symptoms such as nausea, vomiting, dizziness, confusion, and cardiac arrhythmias. It is particularly indicated in life-threatening situations, such as ventricular fibrillation or severe bradycardia. The decision to use Digibind is based on clinical assessment, including the presence of symptoms, serum digoxin levels, and the patient's medical history.
